InflaRx NV

IFRX

Company Profile

  • Business description

    InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

  • Contact

    Winzerlaer Strasse 2
    Jena07745
    DEU

    T: +49 3641508180

    E: [email protected]

    https://www.inflarx.de

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    74

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,635.5010.600.12%
CAC 407,788.1038.69-0.49%
DAX 4024,038.19188.30-0.78%
Dow JONES (US)42,098.70244.95-0.58%
FTSE 1008,726.0152.04-0.59%
HKSE23,258.31123.68-0.53%
NASDAQ19,100.9498.22-0.51%
Nikkei 22538,177.57455.171.21%
NZX 50 Index12,291.5370.73-0.57%
S&P 5005,888.5532.99-0.56%
S&P/ASX 2008,407.0010.100.12%
SSE Composite Index3,339.730.20-0.01%

Market Movers